Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy

The tumor microenvironment has emerged as a novel chemotherapeutic strategy in the treatment of cancer. This is most clearly exemplified by the antiangiogenesis class of compounds. Therapeutic strategies that target fibroblasts within the tumor stroma offer another treatment option. However, despite promising data obtained in preclinical models, such strategies have not been widely used in the clinical setting, largely due to a lack of effective treatments that specifically target this population of cells. The identification of fibroblast activation protein α (FAP) as a target selectively expressed on fibroblasts within the tumor stroma or on carcinoma-associated fibroblasts led to intensive efforts to exploit this novel cellular target for clinical benefit. FAP is a membrane-bound serine protease of the prolyl oligopeptidase family with unique post-prolyl endopeptidase activity. Until recently, the majority of FAP-based therapeutic approaches focused on the development of small-molecule inhibitors of enzymatic activity. Evidence suggests, however, that FAP's pathophysiological role in carcinogenesis may be highly contextual, depending on both the exact nature of the tumor microenvironment present and the cancer type in question to determine its tumor-promoting or tumor-suppressing phenotype. As an alternative strategy, we are taking advantage of FAP's restricted expression and unique substrate preferences to develop a FAP-activated prodrug to target the activation of a cytotoxic compound within the tumor stroma. Of note, this strategy would be effective independently of FAP's role in tumor progression because its therapeutic benefit would rely on FAP's localization and activity within the tumor microenvironment rather than strictly on inhibition of its function. Mol Cancer Ther; 11(2); 257–66. ©2012 AACR.

[1]  Jun Du,et al.  Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug , 2011, Journal of drug targeting.

[2]  M. Gorrell,et al.  Neuropeptide Y, B‐type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein‐α , 2011, The FEBS journal.

[3]  Y. Toiyama,et al.  Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy. , 2011, International journal of oncology.

[4]  D. Kranz Faculty Opinions recommendation of Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. , 2010 .

[5]  James O. Jones,et al.  Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α , 2010, Science.

[6]  Jonathan D. Cheng,et al.  Identification and characterization of the promoter of fibroblast activation protein. , 2010, Frontiers in bioscience.

[7]  W. B. Church,et al.  The dipeptidyl peptidase IV family in cancer and cell biology , 2010, The FEBS journal.

[8]  O. Franco,et al.  Cancer associated fibroblasts in cancer pathogenesis. , 2010, Seminars in cell & developmental biology.

[9]  Chunsheng Zhang,et al.  Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers , 2010, Proceedings of the National Academy of Sciences.

[10]  E. Puré,et al.  Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. , 2009, The Journal of clinical investigation.

[11]  R. Xiang,et al.  Cancer Associated Fibroblasts Promote Tumor Growth and Metastasis by Modulating the Tumor Immune Microenvironment in a 4T1 Murine Breast Cancer Model , 2009, PloS one.

[12]  S. Pandol,et al.  Desmoplasia of pancreatic ductal adenocarcinoma. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  N. Senzer,et al.  Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

[14]  N. Senzer,et al.  Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma , 2009, BMC Cancer.

[15]  E. Puré The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer , 2009, Expert opinion on therapeutic targets.

[16]  K. Landfester,et al.  Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[17]  P. McKee,et al.  Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design. , 2009, Biochemistry.

[18]  M. A. Leroux,et al.  Treatment of inflammatory diseases with mesenchymal stem cells. , 2009, Inflammation & allergy drug targets.

[19]  A. LeBeau,et al.  Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin , 2009, Molecular Cancer Therapeutics.

[20]  Jia Fan,et al.  Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. , 2009, American journal of clinical pathology.

[21]  G. Koh,et al.  Fibroblast activation protein α identifies mesenchymal stromal cells from human bone marrow , 2008, British journal of haematology.

[22]  B. O'connor,et al.  Seprase: an overview of an important matrix serine protease. , 2008, Biochimica et biophysica acta.

[23]  L. Weiner,et al.  Fibroblast Activation Protein and Its Relationship to Clinical Outcome in Pancreatic Adenocarcinoma , 2008, Pancreas.

[24]  C. Fan,et al.  Tumorigenesis and Neoplastic Progression Molecular Characterization of Human Breast Tumor Vascular Cells , 2008 .

[25]  Douglas B. Evans,et al.  Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.

[26]  T. Kole,et al.  Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. , 2008, Biochemistry.

[27]  D. Soprano,et al.  Retinoids in biological control and cancer , 2007, Journal of cellular biochemistry.

[28]  P. McKee,et al.  Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer , 2007, Cancer biology & therapy.

[29]  Ross Tubo,et al.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.

[30]  C. C. Cunningham Talabostat , 2007, Expert opinion on investigational drugs.

[31]  J. Nesland,et al.  Expression of seprase in effusions from patients with epithelial ovarian carcinoma. , 2007, Chinese medical journal.

[32]  E. Ross,et al.  Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer , 2007, Clinical Cancer Research.

[33]  P. McKee,et al.  Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. , 2007, Archives of biochemistry and biophysics.

[34]  G. Mills,et al.  The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis , 2006, Proceedings of the National Academy of Sciences.

[35]  Robert A. Weinberg,et al.  Stromal Fibroblasts in Cancer: A Novel Tumor-Promoting Cell Type , 2006, Cell cycle.

[36]  M. Loeffler,et al.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. , 2006, The Journal of clinical investigation.

[37]  D. Sutherlin,et al.  Selective Inhibition of Fibroblast Activation Protein Protease Based on Dipeptide Substrate Specificity* , 2006, Journal of Biological Chemistry.

[38]  M. Bissell,et al.  Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. , 2006, Annual review of cell and developmental biology.

[39]  W. Fairbrother,et al.  Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly2‐Pro1‐cleaving specificity , 2006, FEBS letters.

[40]  P. McKee,et al.  Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. , 2006, Blood.

[41]  A. Durand,et al.  Catabolism of intracellular N-terminal acetylated proteins: involvement of acylpeptide hydrolase and acylase. , 2005, Biochimie.

[42]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[43]  Thomas Kelly,et al.  Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[44]  N. Fusenig,et al.  Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.

[45]  P. Collins,et al.  Purification, identification and characterisation of seprase from bovine serum. , 2004, The international journal of biochemistry & cell biology.

[46]  Takeshi Watanabe,et al.  PT-100, a Small Molecule Dipeptidyl Peptidase Inhibitor, Has Potent Antitumor Effects and Augments Antibody-Mediated Cytotoxicity via a Novel Immune Mechanism , 2004, Cancer Research.

[47]  T. Ratliff TGF-Beta Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004 .

[48]  Rameen Beroukhim,et al.  Molecular characterization of the tumor microenvironment in breast cancer. , 2004, Cancer cell.

[49]  Yan Huang,et al.  Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. , 2004, Cancer research.

[50]  M. Washington,et al.  TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.

[51]  J. Kozarich,et al.  Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. , 2003, Current opinion in chemical biology.

[52]  Thomas Kelly,et al.  Seprase complexes in cellular invasiveness , 2003, Cancer and Metastasis Reviews.

[53]  S. Larson,et al.  A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  D. Jäger,et al.  Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer , 2003, Oncology Research and Treatment.

[55]  G. Ayala,et al.  Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  Roland L. Dunbrack,et al.  Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. , 2002, Cancer research.

[57]  H. Larjava,et al.  Regulation of Fibroblast Migration on Collagenous Matrix by a Cell Surface Peptidase Complex* , 2002, The Journal of Biological Chemistry.

[58]  D. Irwin Ancient duplications of the human proglucagon gene. , 2002, Genomics.

[59]  A. Schnapp,et al.  Expression of the fibroblast activation protein during mouse embryo development. , 2001, The International journal of developmental biology.

[60]  N. Ohuchi,et al.  Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast , 2001, International journal of cancer.

[61]  A. Schnapp,et al.  Targeted Disruption of Mouse Fibroblast Activation Protein , 2000, Molecular and Cellular Biology.

[62]  J. Park,et al.  Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts* , 1999, The Journal of Biological Chemistry.

[63]  C. Abbott,et al.  Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis , 1999, Hepatology.

[64]  J. Dodt,et al.  Identification of the 170-kDa Melanoma Membrane-bound Gelatinase (Seprase) as a Serine Integral Membrane Protease* , 1997, The Journal of Biological Chemistry.

[65]  J. Healey,et al.  Fibroblast activation protein: Purification, epitope mapping and induction by growth factors , 1994, International journal of cancer.

[66]  J. Healey,et al.  Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Healey,et al.  Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. , 1993, Cancer research.

[68]  D. Powe,et al.  Desmoplasia and its relevance to colorectal tumour invasion , 1993, International journal of cancer.

[69]  L. Old,et al.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[70]  C. Abbott,et al.  Dipeptidyl peptidase (DP) 6 and DP10: novel brain proteins implicated in human health and disease , 2009, Clinical chemistry and laboratory medicine.

[71]  A. Houghton,et al.  FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. , 2004, Oncogene.

[72]  D. Gotley,et al.  Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis , 2003, Thrombosis and Haemostasis.

[73]  James L. Connolly,et al.  Principles of Cancer Pathology , 2003 .

[74]  M J Bissell,et al.  Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. , 1996, Physiological reviews.

[75]  James O. Jones,et al.  Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .